Results 51 to 60 of about 113,904,810 (178)

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

open access: yesCase Reports in Oncology, 2019
Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer ...
Nobuhiko Seki   +12 more
doaj   +1 more source

Investigation of the mechanisms and modulation of irinotecan‐induced emesis in Suncus murinus

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Irinotecan is a widely used chemotherapeutic agent that frequently causes nausea and emesis. Its emetic mechanism of action is poorly understood and the choice of drugs to reduce nausea and emesis is largely empirical. Experimental Approach Using Suncus murinus, we examined (i) the dose–response and temporal profile of ...
Zengbing Lu   +7 more
wiley   +1 more source

Neurokinin-1 receptor antagonist aprepitant regulates autophagy and apoptosis through ROS/JNK pathway in intrahepatic cholangiocarcinoma

open access: yes, 2023
Abstract Intrahepatic cholangiocarcinoma (iCCA) has a poor prognosis and limited treatment options. Aprepitant, a selective NK-1R antagonist, is capable of inhibiting the growth of various tumors in vitro and in vivo. To investigate the cytotoxic effects of aprepitant on the intrahepatic cholangiocarcinoma, we confirmed the expression of SP/NK ...
Yang Yang   +6 more
openaire   +1 more source

Scalp Dysesthesia: Emerging Pathophysiologic Insights and Therapeutic Implications

open access: yesInternational Journal of Dermatology, EarlyView.
Scalp dysesthesia is a chronic condition diagnosed through exclusion. This scoping review synthesized data from 59 patients to identify recurrent clinical features, comorbidities, and management strategies that may support earlier diagnosis. Emerging patterns suggest that neuronal sensitization may underlie common symptoms.
Aditya K. Gupta   +4 more
wiley   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

open access: yesInternational Journal of Cancer, Volume 159, Issue 8, Page 1990-2003, 15 October 2026.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner   +16 more
wiley   +1 more source

Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

open access: yes, 2011
INTRODUCTION: Aprepitant is the only neurokinin (NK(1)) receptor antagonist (RA) approved for prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant is co-administered with a 5-HT(3) RA and a corticosteroid. Although aprepitant is safe,
Herrstedt, Jørn   +3 more
core   +1 more source

Articles Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial [PDF]

open access: yes, 2020
Summary Background Oral aprepitant, a neurokinin-1 receptor antagonist, is recommended in combination with other antiemetic agents for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy in adults, but its ...
Susan Kang   +6 more
core  

Peripheral Neuropathy in Non-Hodgkin’s Lymphoma Patients Receiving Vincristine with and Without Aprepitant/Fosaprepitant

open access: yes, 2020
Background: Peripheral neuropathy is a common treatment-related adverse effect associated with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside the neurokinin-1 (NK-1) receptor antagonists, aprepitant or ...
Edwards, Jessi K.   +3 more
core   +1 more source

Cancer Neuroscience: From Local Neuro–Immune Microenvironments to Systemic Brain–Body Circuitry

open access: yesMedComm, Volume 7, Issue 9, September 2026.
This review outlines the cancer neuroscience paradigm, spanning systemic brain–body circuitry and local neuro–immune–tumor microenvironments. We discuss how tumors promote axonogenesis and pseudo‐synapse formation, and how sensory neuropeptides, such as CGRP, contribute to CD8+ T‐cell exhaustion.
Mingxuan Xie   +7 more
wiley   +1 more source

A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research [PDF]

open access: yesJournal of Pharmaceutical and Biomedical Analysis, 2009
A sensitive and rapid liquid chromatography-tandem mass spectrometry method has been developed for to assess therapeutic exposures of aprepitant in HIV-infected patients and rhesus macaques. The method utilized a simple sample-preparation procedure of protein precipitation with methanol. Chromatographic separation was performed on a reversed phase C(8)
Di, Wu   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy